RESP Stock Overview
A research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Respiratorius AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.80 |
| 52 Week High | SEK 33.00 |
| 52 Week Low | SEK 4.69 |
| Beta | 1.61 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -82.22% |
| 33 Year Change | -95.68% |
| 5 Year Change | -96.47% |
| Change since IPO | -81.54% |
Recent News & Updates
Shareholder Returns
| RESP | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | n/a | 5.8% | 1.5% |
| 1Y | -82.2% | 17.5% | 11.7% |
Return vs Industry: RESP underperformed the Swedish Biotechs industry which returned 17.9% over the past year.
Return vs Market: RESP underperformed the Swedish Market which returned 12.3% over the past year.
Price Volatility
| RESP volatility | |
|---|---|
| RESP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: RESP's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: Insufficient data to determine RESP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 0 | Johan Drott | www.respiratorius.com |
Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company’s products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.
Respiratorius AB (publ) Fundamentals Summary
| RESP fundamental statistics | |
|---|---|
| Market cap | SEK 24.47m |
| Earnings (TTM) | -SEK 8.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.0x
P/E RatioIs RESP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RESP income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 761.39k |
| Gross Profit | -SEK 761.39k |
| Other Expenses | SEK 7.39m |
| Earnings | -SEK 8.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RESP perform over the long term?
See historical performance and comparison